More MS news articles for Sep 2001

14-3-3 protein in the CSF as prognostic marker in early multiple sclerosis

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11524491&dopt=Abstract

Neurology 2001 Aug 28;57(4):722-724
Martinez-Yelamos A, Saiz A, Sanchez-Valle R, Casado V, Ramon JM, Graus F, Arbizu T.

Service of Neurology (Drs. Martinez-Yelamos, Casado, and Arbizu) and Preventive Medicine (Dr. Ramon), Ciutat Sanitaria Universitaria de Bellvitge, L'Hospitalet, and Service of Neurology (Drs. Saiz, Sanchez-Valle, and Graus), Institut d'Investigacio Biomedica August Pi i Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, Spain.

Axonal damage probably occurs early in the evolution of MS. Five of 38 (13%) patients had a positive assay for the neuronal 14-3-3 protein in the CSF obtained at the first clinically isolated syndrome suggestive of MS.

A positive 14-3-3 assay was the only independent predictor for a shorter time to conversion to clinical definite MS (risk ratio 4.1; 95% CI 1.1 to 15) and to reach an Expanded Disability Status Scale (EDSS) >/=2 at the end of follow-up (odds ratio 14.8; 95% CI 2.86 to 76.8).

The detection of the 14-3-3 protein in the CSF at the first neurologic event suggestive of MS may be a useful predictor of short-term evolution.

PMID: 11524491 [PubMed - as supplied by publisher]